Predicted Molecular Wt: 70kDa Purity: ProA affinity purified IgG Species Cross-reactivity: Human Form: Liquid Applications: IHC-P Swissprot ID: P40967
Background: PMEL 17 isa melanosome specific antigen, also is designed as HMB45 or gp100. It plays acentral role in the biogenesis of melanosomes, involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. PMEL 17 is presented in immature and activated melanocytes (due to, e.g., inflammation, increased vascularity or underlying tumor), but not in mature, resting melanocytes. In tumor tissues, it is restricted expressed in melanoma. Studies support the routine use of PMEL 17 (HMB45) as a sensitive and specific melanocytic marker. Subcellular location: Cytoplasm Recommended method: Heat induced epitope retrieval with Tris-EDTA buffer (pH 9.0), primary antibody incubate at RT (18°C-25°C) for 30 minutes. Immunogen: Synthetic peptide corresponding to PMEL 17 residues within aa561‐661 of PMEL 17 was used as an immunogen. Storage Buffer: PBS 59%, Sodium azide 0.01%, Glycerol 40%, BSA 0.05%. Storage conditions: -25°C to -18°C Storage instructions: Shipped on blue ice. Upon delivery, aliquot, and store at -25°C to -18°C. Avoid freeze / thaw cycles. Recommended Dilutions: IHC-P: 1:100-1:200 Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections analysis of human melanoma tissue labelling PMEL 17 with BP6031. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9.0 Background References: 1. Rothberg BE, et.al, Mod Pathol. 2008 Sep;21(9):1121-9. 2. Wagner SN, et.al, Cancer Immunol Immunother. 1997 Jun;44(4):239-47.
您好!请登录